Under the partnership, the SeePlex assays will be marketed and distributed outside the US, for use with the LabChip Dx through Seegene’s extensive network of global distributors.
The parties will co-market Caliper’s LabChip Dx platform and Seegene’s complete line of multiplex diagnostic content effective immediately.
Seegene and Caliper intend to work together to commercialize selected diagnostic assays with improved sensitivity and specificity while reducing overall costs.
The LabChip Dx system, developed in collaboration with Seegene, enables high throughput, multiplex, cost effective sample processing for discovery and validation of molecular and companion diagnostics.
Seegene’s Dual Priming Oligonucleotide (DPO) approach to PCR-based assays uses a new technique for DNA priming which is structurally and functionally different from traditional PCR priming.
Caliper Life Sciences president and CEO Kevin Hrusovsky said the agreement to partner with Seegene’s multiplex diagnostic content on the LabChip Dx platform should improve the economics of diagnostic testing and pave the way for the development of critical diagnostics to accelerate the worldwide implementation of personalized medicine.
"We believe that Seegene’s DPO technology enables sensitive and specific, highly multiplexed assays directly from clinical samples, significantly improving the economics of today for centralized and hospital based diagnostic testing," Hrusovsky said.
